HER2-targeted ADCs are designed to target HER2-expressing cancer cells and release chemotherapy agents inside cancer cells; the released chemotherapy agents can also be taken up by neighboring cancer cells without HER2 expression, causing cell death [6]. The gene discussed is ERBB2; the disease is cancer.